An EAP Treatment Protocol of Zipalertinib
NCT07601399 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-05-22
Summary
The objective of the study is to provide access to zipalertinib to patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations whose disease has progressed on or after platinum-based chemotherapy with or without amivantamab.
Conditions
Interventions
- DRUG
-
Zipalertinib
Participants will self-administer 100 mg dose, orally, twice daily (BID), continuously in 28-day cycles.
Sponsors & Collaborators
-
Taiho Oncology, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691 ·Status: RECRUITING
-
Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer
NCT04599712 ·Status: APPROVED_FOR_MARKETING
-
Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21
NCT01714908 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
NCT07586202 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
NCT05962021 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
NCT01998126 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
NCT02094573 ·Status: COMPLETED ·Phase: PHASE2
-
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
NCT07229339 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation
NCT00874419 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib
NCT05204628 ·Status: UNKNOWN ·Phase: PHASE3
-
S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00661193 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive
NCT07063329 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca
NCT02036359 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
NCT06671379 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family
NCT00779389 ·Status: COMPLETED ·Phase: PHASE1
-
Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation
NCT01996098 ·Status: TERMINATED ·Phase: PHASE3
-
Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC
NCT05583188 ·Status: TERMINATED ·Phase: PHASE4
-
Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer
NCT00651833 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer
NCT03607188 ·Status: COMPLETED ·Phase: PHASE1
-
Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC
NCT06841874 ·Status: NO_LONGER_AVAILABLE
-
A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
NCT07414927 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
NCT00085839 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
NCT04603807 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer
NCT02973763 ·Status: TERMINATED ·Phase: PHASE1